1-(1H-benzoimidazole-2-carbonyl)-piperidine | 73903-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(1H-benzoimidazole-2-carbonyl)-piperidine
• 英文别名: 1H-benzimidazol-2-yl(piperidin-1-yl)methanone
• CAS: 73903-00-1
• 化学式: C₁₃H₁₅N₃O
• 分子量: 229.282
• InChiKey: HKSNOQWMJLCGBB-UHFFFAOYSA-N

物化性质

• 熔点：
  173-174 °C(Solv: benzene (71-43-2))
• 沸点：
  427.8±28.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯并咪唑 在 苯磺酸 、 lithium diisopropyl amide 作用下， 以 正庚烷 、 甲苯 为溶剂， 反应 15.0h， 生成 1-(1H-benzoimidazole-2-carbonyl)-piperidine
  参考文献：
  名称：

  Why are benzimidazoles efficiently acylated with esters? Identification of a tetrahedral hemiacetal alkoxide intermediate

  摘要：

  2-Lithio benzimidazoles were acylated with esters, lactones, and lactams. The tetrahedral hemiacetal intermediates responsible for the efficient conversion were characterized by low temperature NMR. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2005.05.068

文献信息

• [EN] SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE LA MODIFICATION LIÉE AU SUMO DE CRMP2 ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2018144900A1

  公开（公告）日：2018-08-09

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有哌啶基苯并咪唑结构的小分子，其作为小泛素样修饰物（SUMO）相关修饰（SUMOylation）的抗体，用作治疗与电压门控钠通道1.7（Nav1.7）相关的瘙痒、嗅觉丧失、偏头痛事件和/或疼痛（例如，神经病性疼痛）的治疗药物。
• Anti-psychotic compounds
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0411631A1

  公开（公告）日：1991-02-06

  The present invention is directed to a new class of therapeutic agent of the formula: in which Y is represented by CO or CHOH; T is represented by CO or CHOH; X is represented by hydrogen or a C₁₋₆ alkyl; n is represented by the integer 3 or 4; R and R₁ are each independently represented by hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, -OH or -CF₃; and pharmaceutically acceptable acid addition salts thereof, which are useful as anti-psychotic agents and as analgesics.

  本发明涉及一类新的治疗剂，其式如下 其中 Y 由 CO 或 CHOH 表示；T 由 CO 或 CHOH 表示；X 由氢或 C₁₋₆ 烷基表示；n 由整数 3 或 4 表示；R和R₁各自独立地由氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、-OH或-CF₃代表；以及它们的药学上可接受的酸加成盐，可用作抗精神病药和镇痛药。
• Why are benzimidazoles efficiently acylated with esters? Identification of a tetrahedral hemiacetal alkoxide intermediate
  作者：Ken-ichi Asakawa、J.J. Dannenberg、Kenneth J. Fitch、Stan S. Hall、Chie Kadowaki、Sandor Karady、Satoshi Kii、Kenji Maeda、Benjamin F. Marcune、Toshiaki Mase、Ross A. Miller、Robert A. Reamer、David M. Tschaen

  DOI：10.1016/j.tetlet.2005.05.068

  日期：2005.7

  2-Lithio benzimidazoles were acylated with esters, lactones, and lactams. The tetrahedral hemiacetal intermediates responsible for the efficient conversion were characterized by low temperature NMR. (c) 2005 Published by Elsevier Ltd.